Copy number loss of the interferon gene cluster in melanomas is linked to reduced T cell infiltrate and poor patient prognosis

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Linsley, Peter S ^a   Speake, Cate ^a   Whalen, Elizabeth ^a   Chaussabel, Damien ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; INTERFERON; OSTEOCLAST DIFFERENTIATION FACTOR;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CDKN2A GENE; CDKN2B GENE; CHROMOSOMAL LOCALIZATION; CHROMOSOME 9P; COHORT ANALYSIS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE CLUSTER; GENE EXPRESSION REGULATION; GENE LOSS; HELPER CELL; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; INTERFERON GENE; INTERFERON STIMULATED GENE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; NATURAL KILLER CELL; NUCLEOTIDE SEQUENCE; PREDICTION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SKIN CUTANEOUS MELANOMA; T LYMPHOCYTE; TNFSF11 GENE; COPY NUMBER VARIATION; GENE EXPRESSION; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; MORTALITY; MULTIGENE FAMILY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SKIN TUMOR;

DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION; HUMANS; INTERFERON TYPE I; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; MULTIGENE FAMILY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 84907994039     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109760     Document Type: Article

References (40)

1. Couzin-Frankel J (2013) Cancer Immunotherapy. Science 342: 1432-1433. doi:10.1126/science.342.6165.1432.
2. Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39: 1-10. doi:10.1016/j.immuni.2013.07.012.
3. Acharya UH, Jeter JM (2013) Use of ipilimumab in the treatment of melanoma. Clin Pharmacol Adv Appl 5: 21-27. doi:10.2147/CPAA.S45884.
4. Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, et al. (2011) A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 9: 204. doi:10.1186/1479-5876-9-204.
5. Galon J, Angell HK, Bedognetti D, Marincola FM (2013) The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39: 11-26. doi:10.1016/j.immuni.2013.07.008.
6. Ascierto ML, De Giorgi V, Liu Q, Bedognetti D, Spivey TL, et al. (2011) An immunologic portrait of cancer. J Transl Med 9: 146. doi:10.1186/1479-5876-9-146.
7. Catchpoole DR, Kennedy P, Skillicorn DB, Simoff S (2010) The curse of dimensionality: a blessing to personalized medicine. J Clin Oncol Off J Am Soc Clin Oncol 28: e723-724; author reply e725. doi:10.1200/JCO.2010.30.1986.
8. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, et al. (2008) A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29: 150-164. doi:10.1016/j.immuni.2008.05.012.
9. Novershtern N, Subramanian A, Lawton LN, Mak RH, Haining WN, et al. (2011) Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell 144: 296-309. doi:10.1016/j.cell.2011.01.004.
10. Li B, Dewey CN (2011) RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12: 323. doi:10.1186/1471-2105-12-323.
11. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, et al. (2013) STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 41: D808-815. doi:10.1093/nar/gks1094.
12. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504. doi:10.1101/gr.1239303.
13. R Core Team (2013) A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. Available: http://www.R-project.org/.
14. Wickham H (2009) ggplot2: elegant graphics for data analysis. Available: http://had.co.nz/ggplot2/book.
15. Wickham H (2007) Reshaping Data with the reshape Package. J Stat Softw 21: 1-20.
16. Hothorn T, Hornik K, Strobl C, Zeileis A (n.d.) party: A Laboratory for Recursive Partytioning. Available: http://cran.r-project.org/web/packages/party/index.html.
17. Therneau TM, Grambsch PM (2000) Modeling Survival Data: Extending the Cox Model. New York: Springer.
18. Therneau T (n.d.) A Package for Survival Analysis in S-. R package version 2.37-4. Available: http://CRAN.R-project.org/package=survival.
19. Abhijit GT, Cowley M (2011) An enhanced Kaplan-Meier plot. R. Available: http://www.r-bloggers.com/an-enhanced-kaplan-meier-plot/.
20. Banchereau R, Jordan-Villegas A, Ardura M, Mejias A, Baldwin N, et al. (2012) Host immune transcriptional profiles reflect the variability in clinical disease manifestations in patients with Staphylococcus aureus infections. PloS One 7: e34390. doi:10.1371/journal.pone.0034390.
21. Quaglino P, Marenco F, Osella-Abate S, Cappello N, Ortoncelli M, et al. (2010) Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol Off J Eur Soc Med Oncol ESMO 21: 409-414. doi:10.1093/annonc/mdp325.
22. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, et al. (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354: 709-718. doi:10.1056/NEJMoa053007.
23. Shay T, Jojic V, Zuk O, Rothamel K, Puyraimond-Zemmour D, et al. (2013) Conservation and divergence in the transcriptional programs of the human and mouse immune systems. Proc Natl Acad Sci U S A 110: 2946-2951. doi:10.1073/pnas.1222738110.
24. Jönsson G, Busch C, Knappskog S, Geisler J, Miletic H, et al. (2010) Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res Off J Am Assoc Cancer Res 16: 3356-3367. doi:10.1158/1078-0432.CCR-09-2509.
25. Ji R-R, Chasalow SD, Wang L, Hamid O, Schmidt H, et al. (2012) An immuneactive tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother CII 61: 1019-1031. doi:10.1007/s00262-011-1172-6.
26. Mann GJ, Pupo GM, Campain AE, Carter CD, Schramm S-J, et al. (2013) BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol 133: 509-517. doi:10.1038/jid.2012.283.
27. Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, et al. (2013) Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol Off J Am Soc Clin Oncol 31: 2388-2395. doi:10.1200/JCO.2012.44.3762.
28. Fuertes MB, Woo S-R, Burnett B, Fu Y-X, Gajewski TF (2013) Type I interferon response and innate immune sensing of cancer. Trends Immunol 34: 67-73. doi:10.1016/j.it.2012.10.004.
29. Dunn GP, Bruce AT, Sheehan KCF, Shankaran V, Uppaluri R, et al. (2005) A critical function for type I interferons in cancer immunoediting. Nat Immunol 6: 722-729. doi:10.1038/ni1213.
30. Bishop DT, Demenais F, Iles MM, Harland M, Taylor JC, et al. (2009) Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 41: 920-925. doi:10.1038/ng.411.
31. Chatzinasiou F, Lill CM, Kypreou K, Stefanaki I, Nicolaou V, et al. (2011) Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma. J Natl Cancer Inst 103: 1227-1235. doi:10.1093/jnci/djr219.
32. Falchi M, Bataille V, Hayward NK, Duffy DL, Bishop JAN, et al. (2009) Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet 41: 915-919. doi:10.1038/ng.410.
33. Lenci RE, Bevier M, Brandt A, Bermejo JL, Sucker A, et al. (2012) Influence of genetic variants in type I interferon genes on melanoma survival and therapy. PloS One 7: e50692. doi:10.1371/journal.pone.0050692.
34. Mitelman F, Mertens F, Johansson B (1997) A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet 15: 417-474. doi:10.1038/ng0497supp-417.
35. Rákosy Z, Vízkeleti L, Ecsedi S, Bégány A, Emri G, et al. (2008) Characterization of 9p21 copy number alterations in human melanoma by fluorescence in situ hybridization. Cancer Genet Cytogenet 182: 116-121. doi:10.1016/j.cancergencyto.2008.01.008.
36. Fountain JW, Karayiorgou M, Ernstoff MS, Kirkwood JM, Vlock DR, et al. (1992) Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A 89: 10557-10561.
37. Olopade OI, Jenkins RB, Ransom DT, Malik K, Pomykala H, et al. (1992) Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. Cancer Res 52: 2523-2529.
38. Mlecnik B, Bindea G, Angell HK, Sasso MS, Obenauf AC, et al. (2014) Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med 6: 228ra37. doi:10.1126/scitranslmed.3007240.
39. Lauwerys BR, Hachulla E, Spertini F, Lazaro E, Jorgensen C, et al. (2013) Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon a-kinoid. Arthritis Rheum 65: 447-456. doi:10.1002/art.37785.
40. Hothorn T, Hornik K, Zeileis A (2006) Unbiased Recursive Partitioning: A Conditional Inference Framework. J Comput Graph Stat 15: 651-674.